Hayat — meaning ‘life’ in Arabic — is the first indigenous Covid-19 vaccine in the region to be manufactured by a newly created joint venture between Abu Dhabi’s G42 and Sinopharm.
Hayat — meaning ‘life’ in Arabic — is the first indigenous Covid-19 vaccine in the region to be manufactured by a newly created joint venture between Abu Dhabi’s G42 and Sinopharm. Hayat-Vax is the same Sinopharm vaccine that was registered by the UAE Ministry of Health and Prevention in December last year.
In a statement, G42 revealed that the joint venture is already producing Hayat-Vax with its partner — Ras Al Khaimah-based pharma firm Julphar — with an initial capacity of 2 million doses per month.
This announcement comes a day after Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, and Chinese Foreign Minister, Wang Yi, launched a joint project by G42 and Sinopharm to start a production line in the UAE.
Now, a purpose-built research and development hub for life sciences, biotechnology and vaccine production — the first-of-its-kind in the Arab world — is being set up in Khalifa Industrial Zone Abu Dhabi (Kizad).
The new vaccine plant will become operational this year and, over its phased development, will have a production capacity of 200 million doses per annum across three filling lines and five automated packaging lines.
To view full article, visit Alkhaleejtimes.com